drugset / Trial / NCT06193902
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
NaSequentialOpen-labelTreatment
Summary
This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.
Timeline
- Start
- 2023-11-13
- Primary completion
- 2029-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LEU011 | Cell therapy | — | Intravenous |
Indications
No indication recorded.